2018 sales of the Galenica Group

Galenica increased its consolidated net sales by 0.8% to CHF 3,165.5 million in 2018. This solid performance in the current market environment was achieved thanks to organic growth in all Business sectors and the expansion of the pharmacy network. The Retail Business sector performed particularly well, with an increase in sales of 3.1%. Growth was hampered by additional and higher than originally announced price reduction measures for medications by the authorities.

The company also achieved sustainable improvements in profitability in 2018. The management of the Galenica Group is therefore confident of achieving the announced EBIT growth (excluding the effects of IAS 19) for financial year 2018. Consequently, the outlook regarding proposal of a dividend of at least at the same level as the prior year to the Annual General Meeting in 2019 is unchanged.

^{1) Sales figures for 2017 have been restated in line with the new IFRS 15 accounting standards, which came into effect on 1 January 2018.}